MADISON, N.J., Jan. 31 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , announced today that it is adding 52 drug development positions to open a second drug development line at its Wyeth BioPharma Campus in Andover, Mass. beginning in January 2005. With the addition of these biotech jobs, Wyeth will employ more than 2,700 people in Massachusetts between its Wyeth Research Campus in Cambridge, Mass. and its Andover facility.
"Wyeth has one of the strongest pipelines in the biopharmaceutical industry, with significant investment in developing drugs for cancer, Alzheimer's disease, cardiovascular disease, metabolic disorders, inflammation, and other conditions," said Robert Adamson, Ph.D., Vice President, Network Development, Wyeth BioPharma. "The additional capacity provided by a second drug development line will help meet the increased demand for clinical trial supplies for Wyeth's growing number of biotechnology investigational therapies."
Biopharmaceuticals are protein therapies derived from a recombinant DNA sequence involved in the biological process of a disease. The 52 new positions will include scientists, engineers, and other biopharmaceutical professionals engaged in drug substance development including functions such as process and product development, quality, and site administration.
"Every successful biopharmaceutical discovery comes with the daunting challenge of first establishing robust manufacturing technology and then providing reproducible clinical samples. Biopharmaceuticals are complex, protein-based molecules, that are not so much manufactured as they are nurtured. We are excited to add to our talented workforce as we prepare to meet the clinical demand for these important new medicines," said Michael E. Kamarck, Ph.D., Senior Vice President, Wyeth BioPharma.
The 1.1 million square foot Wyeth BioPharma Campus in Andover has more than 1,800 employees, including scientists, engineers and technical experts. As one of the largest biopharmaceutical campuses in the state, Wyeth BioPharma's Andover site includes eight state-of-the-art buildings, two of which are used to develop biopharmaceuticals for use in drug development, including global clinical trials. This is the area adding a second drug development line and the 52 new positions. The other buildings are involved in the manufacture of approved biopharmaceutical therapies including treatments for hemophilia, bone growth, and cancer.
Wyeth Pharmaceuticals, a division of Wyeth , has leading products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products. Wyeth is one of the world's largest research- driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of the timing and success of pharmaceutical research, product development, manufacturing, commercialization, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, wars or terrorist acts, product liability and other types of lawsuits, the impact of legislation and regulatory compliance and obtaining reimbursement, favorable drug pricing, access and other approvals, environmental liabilities, and patent, and other risks and uncertainties, including those detailed from time to time in the Company's periodic reports, including current reports on Form 8-K, quarterly reports on Form 10-Q and the annual report on Form 10-K, filed with the Securities and Exchange Commission. Actual results may vary materially from the forward-looking statements. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Media Contacts: Investor Contact:
Gerald Burr Justin Victoria
Wyeth Pharmaceuticals Wyeth
(484) 865-5138 (973) 660-5340